Katarzyna Pawłowska
07.05.2026 Table of contents
Treatment of obesity In recent years, there has been a significant change in this area thanks to advances in metabolic pharmacotherapy. Medicines that not only support weight loss but also influence the mechanisms regulating appetite, satiety and glucose metabolism are playing an increasingly important role. One of the most frequently discussed preparations is Mounjaro. In a clinical context Mounjaro effects before and after is primarily assessed in the long term, as metabolic changes occur gradually and depend on the regularity of therapy and the patient's lifestyle. Patients very often enter the phrase „Mounjaro effects before and after” to see what the real course of therapy looks like. However, it should be emphasised that the effects are not immediate and show a clear dependence on the dose, lifestyle and individual response of the body. In some patients, the first effects are subtle and mainly concern a reduction in appetite rather than the loss of weight itself.
How does Mounjaro work?
Mounjaro contains thiothiazolidine, a substance that acts on two hormonal mechanisms - GIP and GLP-1. It is the action of these two hormones that is responsible for its effectiveness in reducing body weight and improving metabolic parameters. This mechanism influences the satiety centre in the brain, leading to a faster onset of feelings of fullness. This reduces appetite and patients spontaneously consume fewer calories. Compared to GLP-1-only therapies such as semaglutide, thiothiazolidine shows a broader metabolic effect, which in clinical trials often translates into greater weight reduction, although the body's response remains individual. In many patients using Mounjaro there is also a stabilisation of energy levels throughout the day and a reduced need to snack between meals, which is important for long-term weight control.
Mounjaro and the treatment of type 2 diabetes
Thiogastatide was originally developed in the context of the treatment of type 2 diabetes, and therefore its effects also include improving carbohydrate metabolism. Some patients show improved glycaemic control and a reduction in HbA1c values. This is particularly important in the context of people with type 2 diabetes, in whom weight reduction and improved metabolism reduce the risk of cardiovascular complications. In clinical practice, treatment is carried out as prescribed by the physician, and regular monitoring of parameters such as sugar and HbA1c allows the effectiveness of the therapy to be assessed.
First effects of Mounjaro
During application Mounjaro The first effects are not immediately related to weight reduction. In the first weeks of therapy, a reduction in appetite and easier portion control are most often observed. Many patients also experience a quicker feeling of satiety after meals due to the action on the satiety centre in the brain. As a result, energy intake is reduced without the need for restrictive diets. At this stage of treatment, it is important to keep the body adequately hydrated and to avoid sudden changes in the calorie content of the diet as the body adapts to the new hunger regulation mechanism.
First weeks of application
Clinical studies show that the therapy can lead to an average weight reduction of 15-22% in the long term. The rate of change depends on the dose, diet and level of physical activity.
Weight reduction mainly concerns adipose tissue, including visceral fat, excess of which is associated with an increased risk of metabolic diseases.
- 1-2 weeks: adaptation of the body, reduced appetite, no marked change in weight
- 1 month: improved appetite control, reduction of approx. 1-2 kg
- 5-8 weeks: more noticeable effects, a drop of approx. 3-4 kg
- 9-12 weeks: consolidation of changes, a drop of approx. 5-6 kg
Mounjaro - dosage and mode of application
The drug is administered once a week by subcutaneous injection. Use of Mounjaro starts with a low dose, which is then gradually increased. The dose of the drug is always determined by the doctor, taking into account the patient's tolerance and possible side effects. This approach minimises the risk of gastrointestinal symptoms and improves the safety of the therapy. In clinical practice, the use of Mounjaro requires regular monitoring and assessment of the body's response to subsequent treatment steps.
Effects in the following months of treatment
In the following months of regular therapy, there is a more pronounced reduction in body fat. In clinical trials, weight reduction ranges from 5 to 10% on average over 2-3 months of treatment. During this time, regular physical activity, including strength training, is particularly important to support the maintenance of muscle mass and improve insulin sensitivity. The combination of pharmacotherapy, diet and exercise leads to the best metabolic effects and more stable weight loss.
Long-term effects
After approximately 24-72 weeks of therapy, weight reduction of up to 15-22% is possible. In practice, this means a significant improvement in health parameters and a reduction in the risk of cardiovascular disease. During this period, not only body weight is improved, but also glycaemic control, lipid profile and overall metabolic condition of the body.
Lifestyle and the importance of activity
The effectiveness of therapy has a direct relationship to lifestyle. Mounjaro supports the weight reduction process, but is not a substitute for changing habits. The best results are achieved by patients who combine treatment with diet, calorie control and regular physical activity.
Side effects, contraindications and precautions
Like any medicine, Mounjaro may cause side effects. These are most often transient and include nausea, flatulence, diarrhoea or constipation. Some patients may also experience vomiting, especially at the beginning of therapy. These symptoms are usually mild and subside as the body adapts. In the case of gastrointestinal diseases, caution and individual risk assessment are necessary. The doctor also analyses contraindications, including thyroid disease and other risk factors, before starting treatment.
Mounjaro in practice - the pace of change
The rate of weight reduction depends on many factors. For some patients, the effects appear faster, for others slower, which is natural and a result of the body's individual response. Therefore, the effects should not be compared between patients, as every body reacts differently to drug therapy.
Mounjaro effects before and after - what real difference does the therapy make?
Mounjaro effects before and after include progressive weight reduction, improved metabolic parameters and better appetite control. The mechanism of action is based on the regulation of the hormones GIP and GLP-1, which affects satiety, glucose and metabolism. Effects appear gradually, ranging from a reduction in appetite in the first weeks of therapy to a marked reduction in body weight in the following months. The effectiveness of treatment depends on the dose, lifestyle, physical activity and the patient's cooperation with the doctor.
Would you like to know more? The modern approach to treating obesity includes both metabolic drug therapy and treatment procedures supporting fat reduction and improving body composition. At Wellclinic, we offer body-contouring treatments which form part of a comprehensive programme to support weight loss and body shaping. Consult with our medical staff, who tailor the therapy to your needs.
Sources:
1. FDA (U.S. Food and Drug Administration)
https://www.fda.gov/
2. PubMed „New Drug: Tirzepatide (Mounjaro™)” https://pubmed.ncbi.nlm.nih.gov/36751934/
3. PubMed „Weight loss efficacy and safety of tirzepatide: A systematic review” https://pmc.ncbi.nlm.nih.gov/articles/PMC10159347/
4. EMA (European Medicines Agency) https://www.ema.europa.eu/
„Mounjaro” https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro
5. Healthline „Mounjaro for Weight Loss„
https://www.healthline.com/health/drugs/mounjaro-for-weight-loss
Frequently asked questions
Eligibility for Mounjaro therapy for the treatment of obesity begins with a detailed medical consultation, during which the patient’s general state of health, medical history and previous weight-loss methods are assessed. The doctor also analyses metabolic factors, lifestyle and any potential contraindications to treatment. On this basis, a decision is made as to whether Mounjaro can be included as part of the treatment plan. An important part of the process is also setting realistic treatment goals and discussing the safety guidelines for using the medicine. Eligibility is assessed on an individual basis and always takes into account the patient’s full clinical picture, to ensure that the treatment is both effective and safe.
The speed at which Mounjaro works in the treatment of obesity varies and depends on a number of individual factors. These include, amongst others, metabolism, level of physical activity, hormonal balance and daily eating habits. In some patients, the effects may become apparent more quickly, whilst in others the process is gradual and takes longer. Differences also stem from initial body weight and overall physical condition. Mounjaro works through metabolic mechanisms; however, the body’s response to treatment is always individual, so the effects should not be compared across patients.
Mounjaro, when used to treat obesity, can form part of a broader, comprehensive therapeutic approach that also includes treatments to support fat reduction and body contouring. In clinical practice, this combined approach is sometimes used to enhance the effects of the overall weight-loss process. Body treatments can help improve body contour, reduce localised fat deposits and improve skin firmness, but they are not a substitute for pharmacotherapy. It is crucial to tailor the treatment plan to the individual so that Mounjaro and the treatments form a coherent part of the weight-loss strategy.
Mounjaro, when used to treat obesity, can support weight loss; however, its effectiveness largely depends on making concurrent lifestyle changes. This means that the best results are seen in patients who make changes to their diet, increase their physical activity and ensure they eat at regular intervals. Mounjaro does not replace these elements, but it can make it easier to implement them by influencing feelings of fullness and appetite control. In clinical practice, it is regarded as a supportive measure rather than the sole treatment for obesity; therefore, a comprehensive approach is crucial.
Monitoring the effects of Mounjaro therapy in the treatment of obesity is a key element of the overall treatment programme and is carried out on a regular and scheduled basis. The patient remains under the constant supervision of a doctor, who assesses both changes in body weight and the body’s overall response to treatment. Metabolic parameters and the patient’s well-being are also analysed, as the treatment affects not only weight loss but also the body’s overall balance. During follow-up appointments, the doctor may adjust the treatment plan to optimise the effects of Mounjaro therapy and ensure its safety. Regular monitoring also allows for an early response to any potential adverse reactions.
Mounjaro can also be used to treat obesity in people without diabetes; however, the decision to prescribe it always rests with the treating doctor. Treatment is considered on the basis of an individual assessment of the patient’s health, body weight and metabolic factors. The doctor also takes into account the patient’s medical history and any potential contraindications. In clinical practice, Mounjaro is used as part of obesity treatment regardless of whether diabetes is present, as its action involves mechanisms related to the regulation of body weight and metabolism.
+48 600 100 177